128 related articles for article (PubMed ID: 38537953)
1. Roles of Matrix Metalloproteinases 2 and 9 in Uterine Leiomyosarcoma.
Wang X; Li C; Lou L; Zhu H
Anticancer Res; 2024 Apr; 44(4):1465-1473. PubMed ID: 38537953
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic value of Bcl-2 in uterine leiomyosarcoma.
Travaglino A; Raffone A; Raimondo D; Gencarelli A; Esposito I; Gallo C; Improda FP; Vitale SG; Mollo A; Casadio P; Seracchioli R; Zullo F; Insabato L
Arch Gynecol Obstet; 2023 Feb; 307(2):379-386. PubMed ID: 35344084
[TBL] [Abstract][Full Text] [Related]
3. Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma.
Kodama M; Shimura H; Tien JC; Newberg JY; Kodama T; Wei Z; Rangel R; Yoshihara K; Kuruma A; Nakae A; Hashimoto K; Sawada K; Kimura T; Jenkins NA; Copeland NG
Cancer Res; 2021 Nov; 81(21):5413-5424. PubMed ID: 34475109
[TBL] [Abstract][Full Text] [Related]
4. Expression of matrix metalloproteinases in patients with uterine smooth muscle tumors: an immunohistochemical analysis of MMP-1 and MMP-2 protein expression in leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner-Adler B; Bodner K; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):182-6. PubMed ID: 15051038
[TBL] [Abstract][Full Text] [Related]
5. Gamma Secretase Inhibitors as Potential Therapeutic Targets for Notch Signaling in Uterine Leiomyosarcoma.
Abedin Y; Gabrilovich S; Alpert E; Rego E; Begum S; Zhao Q; Heller D; Einstein MH; Douglas NC
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682660
[TBL] [Abstract][Full Text] [Related]
6. The Functional Role and Regulatory Mechanism of Bromodomain-Containing Protein 9 in Human Uterine Leiomyosarcoma.
Yang Q; Bariani MV; Falahati A; Khosh A; Lastra RR; Siblini H; Boyer TG; Al-Hendy A
Cells; 2022 Jul; 11(14):. PubMed ID: 35883603
[TBL] [Abstract][Full Text] [Related]
7. MMP14 expression and collagen remodelling support uterine leiomyosarcoma aggressiveness.
Gonzalez-Molina J; Hahn P; Falcão RM; Gultekin O; Kokaraki G; Zanfagnin V; Braz Petta T; Lehti K; Carlson JW
Mol Oncol; 2024 Apr; 18(4):850-865. PubMed ID: 37078535
[TBL] [Abstract][Full Text] [Related]
8. Targeting Class I Histone Deacetylases in Human Uterine Leiomyosarcoma.
Yang Q; Falahati A; Khosh A; Mohammed H; Kang W; Corachán A; Bariani MV; Boyer TG; Al-Hendy A
Cells; 2022 Nov; 11(23):. PubMed ID: 36497061
[TBL] [Abstract][Full Text] [Related]
9. The Functional Role and Regulatory Mechanism of FTO m
Yang Q; Al-Hendy A
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175660
[TBL] [Abstract][Full Text] [Related]
10. Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma.
George S; Barysauskas C; Serrano C; Oduyebo T; Rauh-Hain JA; Del Carmen MG; Demetri GD; Muto MG
Cancer; 2014 Oct; 120(20):3154-8. PubMed ID: 24923260
[TBL] [Abstract][Full Text] [Related]
11. The value of re-exploration in patients with inadvertently morcellated uterine sarcoma.
Oduyebo T; Rauh-Hain AJ; Meserve EE; Seidman MA; Hinchcliff E; George S; Quade B; Nucci MR; Del Carmen MG; Muto MG
Gynecol Oncol; 2014 Feb; 132(2):360-5. PubMed ID: 24296345
[TBL] [Abstract][Full Text] [Related]
12. p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas.
Anderson SE; Nonaka D; Chuai S; Olshen AB; Chi D; Sabbatini P; Soslow RA
Int J Gynecol Cancer; 2006; 16(2):849-53. PubMed ID: 16681772
[TBL] [Abstract][Full Text] [Related]
13. A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma.
Shan W; Akinfenwa PY; Savannah KB; Kolomeyevskaya N; Laucirica R; Thomas DG; Odunsi K; Creighton CJ; Lev DC; Anderson ML
Clin Cancer Res; 2012 Jun; 18(12):3352-65. PubMed ID: 22535157
[TBL] [Abstract][Full Text] [Related]
14. [The loss of heterozygosity and microsatellite instability analysis in differential diagnostics of leiomyosarcoma and proliferative leiomyoma of the uterus].
Shikeeva AA; Kekeeva TV; Zavalishina LÉ; Andreeva IuIu; Frank GA
Arkh Patol; 2011; 73(4):47-50. PubMed ID: 22164433
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent kinase subunit 2 overexpression promotes tumor progression and predicts poor prognosis in uterine leiomyosarcoma.
Deng Y; Han Q; Mei S; Li H; Yang F; Wang J; Ge S; Jing X; Xu H; Zhang T
Oncol Lett; 2019 Sep; 18(3):2845-2852. PubMed ID: 31452763
[TBL] [Abstract][Full Text] [Related]
16. The selected biomarker analysis in 5 types of uterine smooth muscle tumors.
Zhang Q; Kanis MJ; Ubago J; Liu D; Scholtens DM; Strohl AE; Lurain JR; Shahabi S; Kong B; Wei JJ
Hum Pathol; 2018 Jun; 76():17-27. PubMed ID: 29258902
[TBL] [Abstract][Full Text] [Related]
17. Distinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment.
An Y; Wang S; Li S; Zhang L; Wang D; Wang H; Zhu S; Zhu W; Li Y; Chen W; Ji S; Guo X
BMC Cancer; 2017 Sep; 17(1):639. PubMed ID: 28893210
[TBL] [Abstract][Full Text] [Related]
18. A rare case of uterine leiomyosarcoma metastasis to the duodenum.
Patel JK; Cervellione KL; Sulh M; Patel AA; Gintautas J
Proc West Pharmacol Soc; 2009; 52():8-10. PubMed ID: 22128409
[TBL] [Abstract][Full Text] [Related]
19. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
20. Preoperative clinical characteristics scoring system for differentiating uterine leiomyosarcoma from fibroid.
Zhang G; Yu X; Zhu L; Fan Q; Shi H; Lang J
BMC Cancer; 2020 Jun; 20(1):514. PubMed ID: 32493236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
